{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:02:07Z","timestamp":1780084927385,"version":"3.54.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.biopha.2018.08.066","type":"journal-article","created":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T11:40:58Z","timestamp":1535197258000},"page":"1115-1118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Mast cell population in the development of diabetic nephropathy: Effects of renin angiotensin system inhibition"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0009-1750","authenticated-orcid":false,"given":"Richarlisson Borges","family":"de Morais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Pereira","family":"do Couto Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Nunes Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e3o Rodrigues Ferreira","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Renata","family":"Nakamura Hiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Borges","family":"Bispo-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Coelho Balbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2018.08.066_bib0005","doi-asserted-by":"crossref","first-page":"F1039","DOI":"10.1152\/ajprenal.00371.2003","article-title":"High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells","volume":"286","author":"Vidotti","year":"2004","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.066_bib0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/HYPERTENSIONAHA.108.113480","article-title":"Antihypertensive and renoprotective mechanisms of Renin inhibition in diabetic rats","volume":"52","author":"Carey","year":"2008","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.biopha.2018.08.066_bib0015","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/BF02658509","article-title":"Mast cells and type VIII collagen in human diabetic nephropathy","volume":"39","author":"R\u00fcger","year":"1996","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.biopha.2018.08.066_bib0020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0272-6386(98)70022-8","article-title":"Tubulointerstitial mast cell infiltration in glomerulonephritis","volume":"32","author":"Hiromura","year":"1998","journal-title":"Am. J. Kidney Dis."},{"issue":"7","key":"10.1016\/j.biopha.2018.08.066_bib0025","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1681\/ASN.V1071498","article-title":"Mast cells in rapidly progressive glomerulonephritis","volume":"10","author":"T\u00f3th","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2018.08.066_bib0030","doi-asserted-by":"crossref","first-page":"F1103","DOI":"10.1152\/ajprenal.00374.2007","article-title":"Increased mast cell number in human hypertensive nephropathy","volume":"295","author":"Welker","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.066_bib0035","doi-asserted-by":"crossref","first-page":"F192","DOI":"10.1152\/ajprenal.00562.2010","article-title":"Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model","volume":"302","author":"Veerappan","year":"2012","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2018.08.066_bib0040","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1523-1755.1999.00590.x","article-title":"Molecular mechanisms of diabetic renal hypertrophy","volume":"56","author":"Wolf","year":"1999","journal-title":"Kidney Int."},{"issue":"3 Pt 2","key":"10.1016\/j.biopha.2018.08.066_bib0045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/hy09t1.094234","article-title":"Angiotensin II and renal fibrosis","volume":"38","author":"Mezzano","year":"2001","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.biopha.2018.08.066_bib0050","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1590\/S0100-879X2011007500093","article-title":"Alternative pathways for angiotensin II generation in the cardiovascular system","volume":"44","author":"Becari","year":"2011","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"7","key":"10.1016\/j.biopha.2018.08.066_bib0055","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1745-7254.2008.00812.x","article-title":"Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury","volume":"29","author":"Shao","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.066_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MNH.0b013e328011a20c","article-title":"The role of the renal kallikrein-kinin system in diabetic nephropathy","volume":"16","author":"Riad","year":"2007","journal-title":"Curr. Opin. Nephrol. Hypertens"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218330865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218330865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:40:17Z","timestamp":1766025617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218330865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":12,"alternative-id":["S0753332218330865"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.066","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast cell population in the development of diabetic nephropathy: Effects of renin angiotensin system inhibition","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}